Mosanna Therapeutics is a clinical-stage biotech developing MOS118, a bedtime nasal spray for obstructive sleep apnea (OSA). Rather than mechanically forcing the airway open like CPAP, MOS118 is a small molecule pan-K+ channel inhibitor that reactivates the body's own negative pressure reflex - stimulating pressure-sensing nerves in the nasopharynx to increase upper airway muscle tone and reduce apnea episodes. Founded in 2022 and headquartered in Redwood City, California with an office in Basel, Switzerland, the company launched publicly in June 2025 with an $80 million Series A to advance MOS118 through Phase 2.
Siesta Medical, Inc. is a privately held medical device company in Los Gatos, California that builds minimally invasive implants and instruments to treat obstructive sleep apnea (OSA). Its flagship AIRLIFT procedure - performed with the FDA-cleared Encore System and the Revolution Suture Passer - lets ear, nose and throat surgeons pull the hyoid bone and tongue base forward to keep the airway open during sleep. The knotless, fully adjustable approach takes roughly 30 minutes, works regardless of a patient's anatomy, BMI or apnea severity, and has been used in more than 2,000 patients.